


AOCC2025 - List of Accepted Abstracts (Oral Presentation)

Submission No. 	Presentation No.	Session	Date	Time	Room	The title of abstract
C000131	<b>01-1</b>	Oral Presentation 1	Friday, July 11, 2025	09:00 - 10:15	Room 3	Age-Stratified Efficacy of Upadacitinib in Refractory IBD: An Asian Cohort Study on Pediatric Crohn’s and Geriatric Ulcerative Colitis
C000132	<b>01-2</b>	Oral Presentation 1	Friday, July 11, 2025	09:00 - 10:15	Room 3	Effectiveness and Safety Analysis of Upadacitinib in the Treatment of Inflammatory Bowel Disease: A Multicenter Real-World Study
C000232	<b>01-3</b>	Oral Presentation 1	Friday, July 11, 2025	09:00 - 10:15	Room 3	Therapeutic Preferences of Upadacitinib for Patients with Inflammatory Bowel Diseases: A Nationwide Study Among Chinese Physicians
C000320	<b>01-4</b>	Oral Presentation 1	Friday, July 11, 2025	09:00 - 10:15	Room 3	Real World Outcomes of Upadacitinib Therapy for Patient with Inflammatory Bowel Disease in Korea: A Multicenter study
C000436	<b>01-5</b>	Oral Presentation 1	Friday, July 11, 2025	09:00 - 10:15	Room 3	Efficacy and Safety of Upadacitinib in Chinese Patients with Inflammatory Bowel Disease: A Multicenter, Prospective, Real-World Study (EaseUpIBD Study)
C000417	<b>01-6</b>	Oral Presentation 1	Friday, July 11, 2025	09:00 - 10:15	Room 3	Ustekinumab and low-dose Upadacitinib combination therapy in medically difficult-to-treat patients with Crohn’s disease: a real-world single-center respective cohort study
C000366	<b>01-7</b>	Oral Presentation 1	Friday, July 11, 2025	09:00 - 10:15	Room 3	Endo-histologic outcomes in patients with ulcerative colitis responding to tofacitinib
C000239	<b>01-8</b>	Oral Presentation 1	Friday, July 11, 2025	09:00 - 10:15	Room 3	Long-term Efficacy, Safety, and Dose Reduction of Tofacitinib for Refractory Ulcerative Colitis
C000125	<b>01-9</b>	Oral Presentation 1	Friday, July 11, 2025	09:00 - 10:15	Room 3	Long-term impacts of filgotinib on bowel and systemic symptoms in patients with ulcerative colitis: a post hoc analysis of the SELECTION and SELECTION long-term extension trials
C000031	<b>01-10</b>	Oral Presentation 1	Friday, July 11, 2025	09:00 - 10:15	Room 3	Effectiveness and Safety of Filgotinib in Japanese Patients with Ulcerative Colitis: A Single-Center Retrospective Study
C000048	<b>01-11</b>	Oral Presentation 1	Friday, July 11, 2025	09:00 - 10:15	Room 3	Clinical trajectory of refractory ulcerative colitis from the view point of filgotinib tapering
C000074	<b>01-12</b>	Oral Presentation 1	Friday, July 11, 2025	09:00 - 10:15	Room 3	Combination therapy With Biologics or Small Molecules for Inflammatory Bowel Disease: A Case Series and Meta-analysis
C000357	<b>02-1</b>	Oral Presentation 2	Friday, July 11, 2025	10:30 - 11:45	Room 3	Correlation and assessment of small bowel lesions using cross sectional imaging techniques compared to small intestinal contrast ultrasonography in known small bowel Crohn’s disease (the CACTUS-CD study): a prospective, validating, confirmatory study (NCT 06125678)
C000089	<b>02-2</b>	Oral Presentation 2	Friday, July 11, 2025	10:30 - 11:45	Room 3	Integrating Perspectives on Transabdominal Intestinal Ultrasound in Inflammatory Bowel Disease Management: A Nationwide Cross-sectional Survey of Physicians and Patients in China
C000184	<b>02-3</b>	Oral Presentation 2	Friday, July 11, 2025	10:30 - 11:45	Room 3	Application of Novel Super Resolution Contrast Enhanced Ultrasound Imaging in Assessing Crohn's Disease Activity
C000185	<b>02-4</b>	Oral Presentation 2	Friday, July 11, 2025	10:30 - 11:45	Room 3	Quality Assurance Study on the Application of Intestinal Ultrasonography in Inflammatory Bowel Disease
C000260	<b>02-5</b>	Oral Presentation 2	Friday, July 11, 2025	10:30 - 11:45	Room 3	Development and Validation of a Simple Intestinal Ultrasound Score for Ileocecal Ulcers in Intestinal Behçet's Disease.
C000437	<b>02-6</b>	Oral Presentation 2	Friday, July 11, 2025	10:30 - 11:45	Room 3	Intestinal Ultrasound as an Early Predictor of Endoscopic Response in Crohn’s Disease
C000081	<b>02-7</b>	Oral Presentation 2	Friday, July 11, 2025	10:30 - 11:45	Room 3	Can Non-invasive Evaluation of Small Bowel Strictures in Crohn’s Disease Using Intestinal Ultrasound Predict Findings of Small Bowel Endoscopy?
C000293	<b>02-8</b>	Oral Presentation 2	Friday, July 11, 2025	10:30 - 11:45	Room 3	Real-World Application of Intestinal Ultrasound for Monitoring Ulcerative Colitis in South Korea
C000313	<b>02-9</b>	Oral Presentation 2	Friday, July 11, 2025	10:30 - 11:45	Room 3	INTESTINAL ULTRASOUND – COLITIS SEVERITY INDEX (IUS-CSI): Valdiation of an Intestinal Ultrasound based score of assessing disease activity in Ulcerative Colitis.
C000359	<b>02-10</b>	Oral Presentation 2	Friday, July 11, 2025	10:30 - 11:45	Room 3	Comparing Triple Rectal Ultrasound Imaging Technology in predicting rectal histoendoscopic remission in Ulcerative Colitis (The TRINITY Study): Trans abdominal, Trans-perineal and Endoscopic ultrasound (NCT06717906)
C000427	<b>02-11</b>	Oral Presentation 2	Friday, July 11, 2025	10:30 - 11:45	Room 3	Intestinal ultrasound for response assessment in hospitalized patients with acute severe ulcerative colitis (ASUC)
C000024	<b>03-1</b>	Oral Presentation 3	Friday, July 11, 2025	14:00 - 15:15	Room 3	PROFILE: endoscopic outcomes from a randomized controlled trial of treatment strategies in newly-diagnosed Crohn's disease
C000049	<b>03-2</b>	Oral Presentation 3	Friday, July 11, 2025	14:00 - 15:15	Room 3	Comparison of clinical efficacy among ulcerative colitis patients treated with infliximab, vedolizumab, and ustekinumab as a first-line biologics: Evaluation based on adapted Mayo score
C000065	<b>03-3</b>	Oral Presentation 3	Friday, July 11, 2025	14:00 - 15:15	Room 3	A Multicenter, Randomized Controlled Trial on the Efficacy and Safety of Vedolizumab in Combination with Upadacitinib for Moderate-to-Severe Ulcerative Colitis
C000413	<b>03-4</b>	Oral Presentation 3	Friday, July 11, 2025	14:00 - 15:15	Room 3	High clinical and endoscopic remission rate with Vedolizumab in early CD patients: the 2nd interim analysis from a prospective multicenter interventional study (EARLY CD)

AOCC2025 - List of Accepted Abstracts (Oral Presentation)

Submission No. 	Presentation No.	Session	Date	Time	Room	The title of abstract
C000371	<b>03-5</b>	Oral Presentation 3	Friday, July 11, 2025	14:00 - 15:15	Room 3	Clinical effectiveness of Vedolizumab in Chinese patients for ulcerative colitis: interim results from the VALUE study
C000364	<b>03-6</b>	Oral Presentation 3	Friday, July 11, 2025	14:00 - 15:15	Room 3	Clinical effectiveness of Vedolizumab in Chinese patients with Crohn's Disease: interim results from the VALUE study
C000158	<b>03-7</b>	Oral Presentation 3	Friday, July 11, 2025	14:00 - 15:15	Room 3	Real-world experience of switching from intravenous to subcutaneous vedolizumab in Korean patients with inflammatory bowel disease
C000403	<b>03-8</b>	Oral Presentation 3	Friday, July 11, 2025	14:00 - 15:15	Room 3	VALIDATION OF THE V-CDST IN PATIENTS WITH CROHN'S DISEASE STARTING VEDOLIZUMAB IN HONG KONG
C000217	<b>03-9</b>	Oral Presentation 3	Friday, July 11, 2025	14:00 - 15:15	Room 3	A Clinical Study on the Optimization of Vedolizumab Induction Therapy for Moderate to Severe Active Ulcerative Colitis at Week 10
C000218	<b>03-10</b>	Oral Presentation 3	Friday, July 11, 2025	14:00 - 15:15	Room 3	Clinical study of Five-flavor sophora flavescens enteric-coated capsules combined with vedolizumab in the induction treatment of ulcerative colitis
C000186	<b>03-11</b>	Oral Presentation 3	Friday, July 11, 2025	14:00 - 15:15	Room 3	Efficacy of Etrolizumab in Moderately-Severe Ulcerative Colitis with Previous Anti-TNF Use : A Systematic Review & Meta Analysis of Randomized Clinical Trials
C000175	<b>04-1</b>	Oral Presentation 4	Friday, July 11, 2025	15:30 - 16:45	Room 3	Efficacy and safety of Mirikizumab versus placebo in East Asian patients with moderately-to-severely active Crohn's disease: a post hoc sub-analysis of the global phase 3 VIVID-1 study
C000182	<b>04-2</b>	Oral Presentation 4	Friday, July 11, 2025	15:30 - 16:45	Room 3	Efficacy of mirikizumab in treating East Asian biologic-failed patients with Crohn's disease: a post hoc subanalysis of the global phase 3 VIVID-1 study
C000174	<b>04-3</b>	Oral Presentation 4	Friday, July 11, 2025	15:30 - 16:45	Room 3	Efficacy of mirikizumab in comparison to ustekinumab in East Asian patients with moderately-to-severely active Crohn's disease: post hoc sub-analysis of the phase 3 VIVID-1 study
C000183	<b>04-4</b>	Oral Presentation 4	Friday, July 11, 2025	15:30 - 16:45	Room 3	Efficacy and safety of mirikizumab as induction therapy for Chinese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the phase 3 Lucent-1 study
C000356	<b>04-5</b>	Oral Presentation 4	Friday, July 11, 2025	15:30 - 16:45	Room 3	The efficacy and safety of guselkumab as maintenance therapy in Chinese patients with Moderately to Severely Active Ulcerative Colitis: Results of the QUASAR Maintenance Study
C000362	<b>04-6</b>	Oral Presentation 4	Friday, July 11, 2025	15:30 - 16:45	Room 3	The efficacy and safety of guselkumab versus placebo in Chinese patients with moderately to severely active Crohn's disease: Results of the GALAXI 2 and GALAXI 3 Phase 3 Studies
C000073	<b>04-7</b>	Oral Presentation 4	Friday, July 11, 2025	15:30 - 16:45	Room 3	Comparative effectiveness of Ustekinumab vs. Infliximab in the Management of Perianal fistulizing Crohn’s disease
C000020	<b>04-8</b>	Oral Presentation 4	Friday, July 11, 2025	15:30 - 16:45	Room 3	Short term clinical and endoscopic efficacy of Ustekinumab in Crohn’s disease: Experience from a tertiary care center in Northern India.
C000318	<b>04-9</b>	Oral Presentation 4	Friday, July 11, 2025	15:30 - 16:45	Room 3	Development and Validation of a Machine Learning Model for Predicting Primary Endoscopic Response to Ustekinumab in Crohn's Disease: A Retrospective Multicenter Cohort Study
C000142	<b>04-10</b>	Oral Presentation 4	Friday, July 11, 2025	15:30 - 16:45	Room 3	Baseline Serum Immunoproteomic Analysis Predicts Endoscopic Response to Ustekinumab in Patients with Crohn’s Disease
C000109	<b>04-11</b>	Oral Presentation 4	Friday, July 11, 2025	15:30 - 16:45	Room 3	Long-term efficacy of therapeutic drug monitoring-guided optimization of ustekinumab in Crohn’s disease patients with clinical remission
C000054	<b>04-12</b>	Oral Presentation 4	Friday, July 11, 2025	15:30 - 16:45	Room 3	Novel Endoluminal Parameters to Predict Primary Loss of Response in Patients with Crohn’s Disease: A National Survey and Multi-center Study
C000345	<b>05-1</b>	Oral Presentation 5	Friday, July 11, 2025	09:00 - 10:15	Room 4	Trajectory analyses to optimise third booster COVID-19 vaccination in patients with inflammatory bowel disease: final analyses of the J-COMBAT trial
C000013	<b>05-2</b>	Oral Presentation 5	Friday, July 11, 2025	09:00 - 10:15	Room 4	Bidirectional association of type 2 diabetes mellitus and inflammatory bowel diseases: a large-scale prospective cohort study
C000005	<b>05-3</b>	Oral Presentation 5	Friday, July 11, 2025	09:00 - 10:15	Room 4	The Incidence and Prevalence change of Inflammatory bowel disease in North China: a population-based study from Jinan Medical Insurance Cohort (2005-2022)
C000037	<b>05-4</b>	Oral Presentation 5	Friday, July 11, 2025	09:00 - 10:15	Room 4	Temporal trends in obesity and its prognostic impact in Korean patients with inflammatory bowel disease
C000143	<b>05-5</b>	Oral Presentation 5	Friday, July 11, 2025	09:00 - 10:15	Room 4	Prevalence of Extraintestinal Manifestations in single Chinese Inflammatory Bowel Disease center: Differences from the West and Other Asian Regions?
C000227	<b>05-6</b>	Oral Presentation 5	Friday, July 11, 2025	09:00 - 10:15	Room 4	Geographic Disparities in the Natural Course and Management of Crohn’s Disease in China: A Multicenter Registry Study (CHASE-IBD)
C000261	<b>05-7</b>	Oral Presentation 5	Friday, July 11, 2025	09:00 - 10:15	Room 4	Cancer incidence in patients with inflammatory bowel disease: A nationwide population-based study
C000283	<b>05-8</b>	Oral Presentation 5	Friday, July 11, 2025	09:00 - 10:15	Room 4	Global Burden of Inflammatory Bowel Disease Attributable to PM2.5 Air Pollution: A Systematic Analysis

AOCC2025 - List of Accepted Abstracts (Oral Presentation)

Submission No. 	Presentation No.	Session	Date	Time	Room	The title of abstract
C000421	<b>05-9</b>	Oral Presentation 5	Friday, July 11, 2025	09:00 - 10:15	Room 4	Dietary total antioxidant capacity alleviates the hazards of related surgery, gastrointestinal cancer, and all-cause mortality among individuals with inflammatory bowel disease in a prospective cohort study
C000341	<b>05-10</b>	Oral Presentation 5	Friday, July 11, 2025	09:00 - 10:15	Room 4	Incidence and Risk of Venous Thromboembolism (VTE) among Crohn’s Disease Patients and others : A Systematic Review and Meta-analysis
C000014	<b>05-11</b>	Oral Presentation 5	Friday, July 11, 2025	09:00 - 10:15	Room 4	Increased mortality associated with sarcopenia in inflammatory bowel disease: a long-term prospective cohort study
C000303	<b>05-12</b>	Oral Presentation 5	Friday, July 11, 2025	09:00 - 10:15	Room 4	Association of Depression With Mortality in Patients With Inflammatory Bowel Disease: A Prospective Study in UK Biobank
C000012	<b>05-13</b>	Oral Presentation 5	Friday, July 11, 2025	09:00 - 10:15	Room 4	Adherence to healthy lifestyle, metabolic alternations and lower mortality risk of IBD patients: a prospective cohort and mediation analysis
C000237	<b>06-1</b>	Oral Presentation 6	Friday, July 11, 2025	10:30 - 11:45	Room 4	Long-Term Outcomes of Crohn’s Disease Patients Who Underwent Treatment Modification Based on Capsule Endoscopy Findings
C000066	<b>06-2</b>	Oral Presentation 6	Friday, July 11, 2025	10:30 - 11:45	Room 4	Prediction of Endoscopic Restenosis after Endoscopic Balloon Dilation in Patients with Crohn's Disease: A Machine Learning Approach
C000129	<b>06-3</b>	Oral Presentation 6	Friday, July 11, 2025	10:30 - 11:45	Room 4	Correlation of biomarkers with endoscopic activity and determination of provisional cut-off values to predict endoscopic remission in postoperative Crohn’s disease: results from J-PROSPECT study
C000195	<b>06-4</b>	Oral Presentation 6	Friday, July 11, 2025	10:30 - 11:45	Room 4	Reliability and validity of Linked Color Imaging (LCI) to assess mucosal inflammation in ulcerative colitis
C000196	<b>06-5</b>	Oral Presentation 6	Friday, July 11, 2025	10:30 - 11:45	Room 4	Reliability and validity of Texture and Colour Enhancement Imaging (TXI) to assess mucosal inflammation in ulcerative colitis
C000347	<b>06-6</b>	Oral Presentation 6	Friday, July 11, 2025	10:30 - 11:45	Room 4	Comparing Anti-TNF Agents and Ustekinumab Efficacy on Small Bowel Lesions in Crohn’s Disease: Inverse Probability Weighting with Stabilized Propensity Score Weights
C000367	<b>06-7</b>	Oral Presentation 6	Friday, July 11, 2025	10:30 - 11:45	Room 4	Combining White-Light and Narrow-Band Imaging AI Models for Enhanced Relapse Prediction in Ulcerative Colitis
C000284	<b>06-8</b>	Oral Presentation 6	Friday, July 11, 2025	10:30 - 11:45	Room 4	Clinical significance of endoscopic deep small bowel evaluation after intestinal surgery to predict long-term endoscopic recurrence in patients with postoperative Crohn’s disease: Results from J-PROSPECT study
C000009	<b>06-9</b>	Oral Presentation 6	Friday, July 11, 2025	10:30 - 11:45	Room 4	Development and validation of a novel therapeutic drug monitoring-based nomogram for prediction of primary endoscopic response to anti-TNF therapy in active Crohn’s disease
C000095	<b>06-10</b>	Oral Presentation 6	Friday, July 11, 2025	10:30 - 11:45	Room 4	Integrated microRNA and Clinical Parameters Predict Stricturing Disease Progression in Crohn's Disease: A Prospective Multi-cohort Study
C000161	<b>06-11</b>	Oral Presentation 6	Friday, July 11, 2025	10:30 - 11:45	Room 4	Human knowledge-enhanced large language model chatbot for prediction of intestinal disease progression in patients with Crohn’s disease: A multicenter retrospective study
C000193	<b>06-12</b>	Oral Presentation 6	Friday, July 11, 2025	10:30 - 11:45	Room 4	Fibroblast-derived interleukin-11 as a biomarker to distinguish stricturing Crohn’s disease
C000202	<b>06-13</b>	Oral Presentation 6	Friday, July 11, 2025	10:30 - 11:45	Room 4	Etiological analysis, corticosteroid therapy and follow-up for patients with villous atrophy: IgA may be a potential indicator for lymphoma diagnosis.
C000258	<b>07-1</b>	Oral Presentation 7	Friday, July 11, 2025	14:00 - 15:15	Room 4	Gut Microbial Biomarkers for IBD Diagnosis Identified via Multi-analytical Approaches: A Large-scale Cohort Study
C000080	<b>07-2</b>	Oral Presentation 7	Friday, July 11, 2025	14:00 - 15:15	Room 4	An advanced MRI neurophenotype model reflecting brain-gut interactions predicts disease progression in Crohn’s disease
C000137	<b>07-3</b>	Oral Presentation 7	Friday, July 11, 2025	14:00 - 15:15	Room 4	Optimizing Transmural Healing Definitions in Crohn's Disease: A Comparative Study Using Magnetic Resonance Enterography
C000291	<b>07-4</b>	Oral Presentation 7	Friday, July 11, 2025	14:00 - 15:15	Room 4	Tight Monitoring with Colonoscopy and Magnetic Resonance Enterography Improves Outcomes in Patients with Crohn’s Disease
C000276	<b>07-5</b>	Oral Presentation 7	Friday, July 11, 2025	14:00 - 15:15	Room 4	Revolutionizing Crohn's Disease Diagnosis: Machine Learning-Driven MR Elastography for Precision Detection and Grading of Intestinal Fibrosis
C000079	<b>07-6</b>	Oral Presentation 7	Friday, July 11, 2025	14:00 - 15:15	Room 4	Alterations in the gut microbiome and metabolite interactions are associated with intestinal inflammation severity and MR enterography abnormalities in patients with Crohn's disease
C000110	<b>07-7</b>	Oral Presentation 7	Friday, July 11, 2025	14:00 - 15:15	Room 4	Altered neural phenotypes in Crohn's disease patients with varying degrees of bowel fibrosis
C000290	<b>07-8</b>	Oral Presentation 7	Friday, July 11, 2025	14:00 - 15:15	Room 4	Deep Learning Model Utilizing Stool Images to Predict Clinical Outcomes of Advanced Therapies in Patients with Moderate to Severe Ulcerative Colitis
C000236	<b>07-9</b>	Oral Presentation 7	Friday, July 11, 2025	14:00 - 15:15	Room 4	HLA-C*03:04:01 and HLA-B*15:18:01 as Risk Factors for Anti-TNF Antibody Formation in Taiwanese Inflammatory Bowel Disease Patients
C000238	<b>07-10</b>	Oral Presentation 7	Friday, July 11, 2025	14:00 - 15:15	Room 4	Anti-Integrin $\alpha v \beta 6$ Autoantibodies Predict Treatment Outcomes of Advanced Therapy for Ulcerative Colitis



AOCC2025 - List of Accepted Abstracts (Oral Presentation)

Submission No. 	Presentation No.	Session	Date	Time	Room	The title of abstract
C000323	<b>07-11</b>	Oral Presentation 7	Friday, July 11, 2025	14:00 - 15:15	Room 4	Relationship Between Total Corticosteroid Dose Before Starting Advanced Therapy and Primary Non-Response
C000431	<b>07-12</b>	Oral Presentation 7	Friday, July 11, 2025	14:00 - 15:15	Room 4	A potential tool for evaluating the long-term therapeutic effects of biologics?
C000169	<b>08-1</b>	Oral Presentation 8	Friday, July 11, 2025	15:30 - 16:45	Room 4	Differences in mucosal permeability of colonic mucosa between patients with ulcerative colitis with and without primary sclerosing cholangitis.
C000400	<b>08-2</b>	Oral Presentation 8	Friday, July 11, 2025	15:30 - 16:45	Room 4	Exploring the potential causal effects of primary sclerosing cholangitis on ulcerative colitis risk: A bidirectional two sample Mendelian randomization study
C000302	<b>08-3</b>	Oral Presentation 8	Friday, July 11, 2025	15:30 - 16:45	Room 4	Characteristics of Gut Microbiota and Serum Metabolites Alterations in Ulcerative Colitis Patients with Comorbid Sleep Disorders
C000360	<b>08-4</b>	Oral Presentation 8	Friday, July 11, 2025	15:30 - 16:45	Room 4	Immunoglobulin A nephropathy in associated with inflammatory bowel disease :a single-center retrospective cohort study in Japan
C000438	<b>08-5</b>	Oral Presentation 8	Friday, July 11, 2025	15:30 - 16:45	Room 4	Association Between Smoking Duration and Histological Inflammation in Ulcerative Colitis After Smoking Cessation
C000248	<b>08-6</b>	Oral Presentation 8	Friday, July 11, 2025	15:30 - 16:45	Room 4	Cardiac structure and function in patients with inflammatory bowel disease: a systematic review and meta-analysis
C000354	<b>08-7</b>	Oral Presentation 8	Friday, July 11, 2025	15:30 - 16:45	Room 4	Shared atypical spontaneous brain activity pattern in Crohn’s Disease and Ulcerative Colitis evidence from cortical surface based analysis
C000277	<b>08-8</b>	Oral Presentation 8	Friday, July 11, 2025	15:30 - 16:45	Room 4	Long-Term Efficacy and Safety of Tulisokibart in Participants with Ulcerative Colitis: The Open-Label Extension of the Phase 2 ARTEMIS-UC Study
C000278	<b>08-9</b>	Oral Presentation 8	Friday, July 11, 2025	15:30 - 16:45	Room 4	Long-term Efficacy and Safety of Tulisokibart in Patients with Crohn’s Disease (CD): Results From the Open-label Extension Period of the Phase 2 APOLLO-CD Study
C000404	<b>09-1</b>	Oral Presentation 9	Friday, July 11, 2025	09:00 - 10:15	Room 5	Fecal Microbiota Transplantation for Multidrug-Resistant Organism Decolonisation in patients with Gastrointestinal Diseases favourably modulates Gut Virome and Microbiome: A Randomised, Double-Blind, Sham-Controlled Trial
C000430	<b>09-2</b>	Oral Presentation 9	Friday, July 11, 2025	09:00 - 10:15	Room 5	Infliximab versus Glucocorticoids as First-Line Therapy for Moderate-to-Severe Ulcerative Colitis: A Multicenter, Prospective, Real-World Cohort Study (INSURE Study)
C000072	<b>09-3</b>	Oral Presentation 9	Friday, July 11, 2025	09:00 - 10:15	Room 5	Comparative Efficacy of Anti-TNF Agents and Ustekinumab for the Prevention and Treatment of Postoperative Recurrence in Crohn's Disease: 10 Years of Experience
C000352	<b>09-4</b>	Oral Presentation 9	Friday, July 11, 2025	09:00 - 10:15	Room 5	Development and Validation of a Bayesian Network-Based Surgical Risk Prediction Tool for Patients with Small Bowel Stricturing Crohn's Disease
C000262	<b>09-5</b>	Oral Presentation 9	Friday, July 11, 2025	09:00 - 10:15	Room 5	Dynamic Abdominal Body Composition Changes Improve Prediction of Surgical Risk in Small Bowel Crohn’s Disease Strictures
C000136	<b>09-6</b>	Oral Presentation 9	Friday, July 11, 2025	09:00 - 10:15	Room 5	Allogeneic Mesenchymal Stem Cells Therapy Using Darvadstrocel in Perianal Fistulizing Crohn’s Disease, Promising Choice? : A Systematic Review & Meta Analysis of Randomized Clinical Trials
C000051	<b>09-7</b>	Oral Presentation 9	Friday, July 11, 2025	09:00 - 10:15	Room 5	Clinical features and outcomes of perianal fistulizing Crohn's disease in Korea: A multicenter observational study
C000017	<b>09-8</b>	Oral Presentation 9	Friday, July 11, 2025	09:00 - 10:15	Room 5	Clinical features, treatment strategies and prognosis of Crohn's Disease related anorectal cancer
C000160	<b>09-9</b>	Oral Presentation 9	Friday, July 11, 2025	09:00 - 10:15	Room 5	Investigation on Predictor of Non-Reversal Stoma in Crohn’s Disease Population Underwent Total Colectomy : A Systematic Review & Meta Analysis
C000187	<b>09-10</b>	Oral Presentation 9	Friday, July 11, 2025	09:00 - 10:15	Room 5	Total versus Segmental Colectomy in Crohn’s Disease Patients, Who is Better? : A Systematic Review & Meta Analysis of Cohort Studies
C000344	<b>09-11</b>	Oral Presentation 9	Friday, July 11, 2025	09:00 - 10:15	Room 5	Minimally invasive surgery for ulcerative colitis with attention to complications
C000377	<b>010-1</b>	Oral Presentation 10	Friday, July 11, 2025	10:30 - 11:45	Room 5	The efficacy and safety of a novel solid enteral nutrition biscuits in inducing treatment of moderate-to-severe Crohn's disease: a prospective, open-label, single-center controlled study
C000250	<b>010-2</b>	Oral Presentation 10	Friday, July 11, 2025	10:30 - 11:45	Room 5	Analysis of clinical background in ulcerative colitis affecting Leucine-rich alpha-2 glycoprotein levels
C000139	<b>010-3</b>	Oral Presentation 10	Friday, July 11, 2025	10:30 - 11:45	Room 5	Changes in Serum Bilirubin and Total Bile Acids During Biologic Therapy in Patients with Ulcerative Colitis: A Retrospective Study
C000263	<b>010-4</b>	Oral Presentation 10	Friday, July 11, 2025	10:30 - 11:45	Room 5	Right-Arm Segmental Bioelectrical Phase Angle: a Novel Tool for Long-Term Inflammation Monitoring in Crohn’s Disease
C000339	<b>010-5</b>	Oral Presentation 10	Friday, July 11, 2025	10:30 - 11:45	Room 5	Right-Arm Segmental Bioelectrical Phase Angle: a Novel Tool for Long-Term Inflammation Monitoring in Crohn’s Disease
C000162	<b>010-6</b>	Oral Presentation 10	Friday, July 11, 2025	10:30 - 11:45	Room 5	REDUCED EFFICACY OF ANTI-TNF- A LPHA THERAPY IN ELDERLY IBD PATIENTS: A BAYESIAN PROPENSITY-SCORE ADJUSTED ANALYSIS

AOCC2025 - List of Accepted Abstracts (Oral Presentation)

Submission No. 	Presentation No.	Session	Date	Time	Room	The title of abstract
C000111	<b>O10-7</b>	Oral Presentation 10	Friday, July 11, 2025	10:30 - 11:45	Room 5	Finding appropriate timing for the combination of azathioprine and infliximab: propensity score matching and inverse probability of treatment weighting analysis
C000050	<b>O10-8</b>	Oral Presentation 10	Friday, July 11, 2025	10:30 - 11:45	Room 5	Comparison of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease Before Anti-Tumor Necrosis Factor-a Agents Therapy: TST-Alone Versus a Combination of TST and IGRA
C000410	<b>O10-9</b>	Oral Presentation 10	Friday, July 11, 2025	10:30 - 11:45	Room 5	A quasi-experimental study evaluating effectiveness of partial enteral nutrition combined with exclusion diet in patients with mild to moderately severe ulcerative colitis
C000288	<b>O10-10</b>	Oral Presentation 10	Friday, July 11, 2025	10:30 - 11:45	Room 5	Renal Impairment in Children with Inflammatory Bowel Disease Treated by Tacrolimus: A Real-World Experience in Japan
C000289	<b>O10-11</b>	Oral Presentation 10	Friday, July 11, 2025	10:30 - 11:45	Room 5	Evaluating Point-of-Care Testing in Proactive Infliximab Therapy: Higher Trough Levels Linked to Improved Perianal Fistula Healing in Pediatric Crohn's Disease
C000330	<b>O10-12</b>	Oral Presentation 10	Friday, July 11, 2025	10:30 - 11:45	Room 5	Serological Evidence of Varicella-Zoster Virus Susceptibility in Pediatric IBD Patients: Risks Independent of Treatment Type
C000397	<b>O10-13</b>	Oral Presentation 10	Friday, July 11, 2025	10:30 - 11:45	Room 5	Therapeutic Implications of Anti-Integrin $\alpha v \beta 6$ Antibody in Pediatric Inflammatory Bowel Disease: A Single-Center Retrospective Study
C000256	<b>O11-1</b>	Oral Presentation 11	Friday, July 11, 2025	14:00 - 15:15	Room 5	The Impact of Teleconsultation on Quality of Life in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis of Randomized Controlled Trials
C000207	<b>O11-2</b>	Oral Presentation 11	Friday, July 11, 2025	14:00 - 15:15	Room 5	Effect of Probiotic on Quality of Life in Ulcerative Colitis Patients, Hope or Hype? : A Meta Analysis of Randomized Trials
C000023	<b>O11-3</b>	Oral Presentation 11	Friday, July 11, 2025	14:00 - 15:15	Room 5	Health Related Quality of Life of Inflammatory Bowel Disease Patients and Associated Factors in the Outpatient Unit of Dr. Cipto Mangunkusumo Hospital
C000201	<b>O11-4</b>	Oral Presentation 11	Friday, July 11, 2025	14:00 - 15:15	Room 5	Impact on Work Productivity and Its Association with Fatigue in Newly Diagnosed Patients with Crohn's Disease: A Subanalysis of iCREST-CD
C000395	<b>O11-5</b>	Oral Presentation 11	Friday, July 11, 2025	14:00 - 15:15	Room 5	Structured yoga practices significantly improve quality of life in patients with Ulcerative Colitis in clinical remission: a randomized controlled trial
C000419	<b>O11-6</b>	Oral Presentation 11	Friday, July 11, 2025	14:00 - 15:15	Room 5	The contribution of socioeconomic determinants and environmental susceptibility in incident inflammatory bowel disease: a prospective cohort study
C000118	<b>O11-7</b>	Oral Presentation 11	Friday, July 11, 2025	14:00 - 15:15	Room 5	Gut feels emotion: Psychological distress is associated with alterations of magnetic resonance enterography in patients with Crohn's disease
C000368	<b>O11-8</b>	Oral Presentation 11	Friday, July 11, 2025	14:00 - 15:15	Room 5	Impact of Inflammatory Bowel Disease on Women’s Health in a Low-Middle Income Country: Unveiling The Silent Struggles
C000149	<b>O11-9</b>	Oral Presentation 11	Friday, July 11, 2025	14:00 - 15:15	Room 5	Age Is More Important Than Disease Activity in Affecting Anti-Müllerian Hormone Level in Women with Inflammatory Bowel Disease
C000172	<b>O11-10</b>	Oral Presentation 11	Friday, July 11, 2025	14:00 - 15:15	Room 5	Supporting the sexual well-being of patients with inflammatory bowel disease: A qualitative study of Japanese nursing practices
C000004	<b>O11-11</b>	Oral Presentation 11	Friday, July 11, 2025	14:00 - 15:15	Room 5	Evaluating large language models as patient education tools for inflammatory bowel disease: A comparative study
C000346	<b>O11-12</b>	Oral Presentation 11	Friday, July 11, 2025	14:00 - 15:15	Room 5	Elucidation of the relationship between thrombophilia and immunothrombosis in ulcerative colitis: Roles of activated platelets and neutrophil extracellular traps (NETs)
C000373	<b>O12-1</b>	Oral Presentation 12	Friday, July 11, 2025	15:30 - 16:45	Room 5	A Multicenter Cross-Sectional Survey of Patient-Reported Mesalazine-Related Adverse Events in Ulcerative Colitis: Real-World Evidence from 47 Centers in China
C000259	<b>O12-2</b>	Oral Presentation 12	Friday, July 11, 2025	15:30 - 16:45	Room 5	The Effects of Discontinuing 5-ASA on Clinical Outcomes in Ulcerative Colitis Patients After Inducing Remission by Advanced Therapy: A Multicenter Retrospective Cohort Study
C000041	<b>O12-3</b>	Oral Presentation 12	Friday, July 11, 2025	15:30 - 16:45	Room 5	Prevalence and Clinical Outcomes in Ulcerative Colitis Patients with Aminosalicylate Intolerance: A Multicenter Retrospective I-BRITE Study
C000188	<b>O12-4</b>	Oral Presentation 12	Friday, July 11, 2025	15:30 - 16:45	Room 5	A National Multicenter Survey on the Current Status of 5-ASA Treatment and Awareness among Elderly Patients with Mild to Moderate Ulcerative Colitis in China
C000053	<b>O12-5</b>	Oral Presentation 12	Friday, July 11, 2025	15:30 - 16:45	Room 5	Adherence to Mesalazine in Maintenance Therapy for Ulcerative Colitis: A National Multicenter Survey
C000067	<b>O12-6</b>	Oral Presentation 12	Friday, July 11, 2025	15:30 - 16:45	Room 5	Impact of Concomitant 5-Aminosalicylic Acid on Ustekinumab and Vedolizumab Therapy for Inflammatory Bowel Disease: A Retrospective Medical Claims Analysis
C000353	<b>O12-7</b>	Oral Presentation 12	Friday, July 11, 2025	15:30 - 16:45	Room 5	Outcome of 5-aminosalicylate continuation versus discontinuation in patients with inflammatory bowel disease started on biologic therapy – A systematic review and Meta-analysis

AOCC2025 - List of Accepted Abstracts (Oral Presentation)

Submission No. 	Presentation No.	Session	Date	Time	Room	The title of abstract
C000198	<b>012-8</b>	Oral Presentation 12	Friday, July 11, 2025	15:30 - 16:45	Room 5	Endoscopic severity at presentation and C-reactive protein predict immediate and twelve-month outcomes of second-line medical therapy in acute severe ulcerative colitis
C000372	<b>012-9</b>	Oral Presentation 12	Friday, July 11, 2025	15:30 - 16:45	Room 5	Practices, Patterns, and Challenges in the Management of Acute Severe Ulcerative Colitis in a Low Middle-Income Country: A Survey-Based Study
C000370	<b>012-10</b>	Oral Presentation 12	Friday, July 11, 2025	15:30 - 16:45	Room 5	The Clinical Spectrum of Acute Severe Ulcerative Colitis in the Biologic Era
C000038	<b>012-11</b>	Oral Presentation 12	Friday, July 11, 2025	15:30 - 16:45	Room 5	Comparative Clinical Outcomes of Advanced Therapy in Bio-naïve versus Bio-experienced Patients Hospitalized with Acute Severe Ulcerative Colitis: A Retrospective Cohort Study
C000363	<b>012-12</b>	Oral Presentation 12	Friday, July 11, 2025	15:30 - 16:45	Room 5	PREVALENCE OF CLOSTRIDIoidES DIFFICILE IN MODERATE TO SEVERE ULCERATIVE COLITIS
C000025	<b>013-1</b>	Oral Presentation 13	Friday, July 11, 2025	09:00 - 10:15	Room 6	Exploring the Role of Galactose-Deficient IgA in Ulcerative Colitis: From Biomarker Potential to Cytokine-Driven Mechanisms
C000064	<b>013-2</b>	Oral Presentation 13	Friday, July 11, 2025	09:00 - 10:15	Room 6	Chronic intestinal inflammation causes persistent alterations in DNA methylation and the immunological function of intestinal macrophages
C000085	<b>013-3</b>	Oral Presentation 13	Friday, July 11, 2025	09:00 - 10:15	Room 6	The Antifibrotic Properties of Meflin in Intestinal Fibroblasts Improve Intestinal Fibrosis in Experimental Inflammatory Bowel Disease
C000107	<b>013-4</b>	Oral Presentation 13	Friday, July 11, 2025	09:00 - 10:15	Room 6	Serum lipidomic profile predict disease behavior progression in treatment-naïve patients with Crohn’s disease
C000127	<b>013-5</b>	Oral Presentation 13	Friday, July 11, 2025	09:00 - 10:15	Room 6	DECORIN PREVENTS INTESTINAL FIBROSIS BY SUPPRESSING ATF3 IN CROHN'S DISEASE
C000308	<b>013-6</b>	Oral Presentation 13	Friday, July 11, 2025	09:00 - 10:15	Room 6	Usefulness of fecal eosinophil-derived neurotoxin in the treatment strategy for ulcerative colitis
C000319	<b>013-7</b>	Oral Presentation 13	Friday, July 11, 2025	09:00 - 10:15	Room 6	Genetic and Clinical Characteristics of Difficult-to-Treat Crohn's Disease: Trio-Based Exome Sequencing in 24 Families
C000321	<b>013-8</b>	Oral Presentation 13	Friday, July 11, 2025	09:00 - 10:15	Room 6	Long-term dynamics in mucosal cytokine expression in patients with ulcerative colitis
C000392	<b>013-9</b>	Oral Presentation 13	Friday, July 11, 2025	09:00 - 10:15	Room 6	Serum Metabolomic Characteristics of Patients with Gastrointestinal Behçet's Disease and the Relationship with Prognosis
C000411	<b>013-10</b>	Oral Presentation 13	Friday, July 11, 2025	09:00 - 10:15	Room 6	Sarcopenia Exacerbating Colitis via Modulation of the Colonic S100A9/TLR4 Inflammatory Axis
C000424	<b>013-11</b>	Oral Presentation 13	Friday, July 11, 2025	09:00 - 10:15	Room 6	Treatment of Patient-Derived Colonic Organoids with Urolithin A Reveals Transcriptomic Remodeling of the Intestinal Stem Cell Niche in Ulcerative Colitis: Establishment of a Novel Platform
C000442	<b>013-12</b>	Oral Presentation 13	Friday, July 11, 2025	09:00 - 10:15	Room 6	Serum proteomic and metabonomic profile predict early remission to anti-integrin therapy in patients with moderate to severe ulcerative colitis
C000002	<b>014-1</b>	Oral Presentation 14	Friday, July 11, 2025	10:30 - 11:45	Room 6	Oral highly-virulent pathogenic isolates aggravated colitis through gut microbiota-equal-ER $\beta$ axis
C000019	<b>014-2</b>	Oral Presentation 14	Friday, July 11, 2025	10:30 - 11:45	Room 6	Effects of Different Sized Microplastic Exposure on Gut Microbiota and Inflammatory Responses Ulcerative Colitis
C000090	<b>014-3</b>	Oral Presentation 14	Friday, July 11, 2025	10:30 - 11:45	Room 6	Gut Bacteria Prevotellaceae Related Lithocholic Acid Metabolism Promotes Colonic Inflammation
C000192	<b>014-4</b>	Oral Presentation 14	Friday, July 11, 2025	10:30 - 11:45	Room 6	Butyrate-producing D.welbionis modulates neutrophil function to inhibit intestinal inflammation through the HDACi pathway
C000220	<b>014-5</b>	Oral Presentation 14	Friday, July 11, 2025	10:30 - 11:45	Room 6	Shared and Distinct Features of the Gut Microbiome Signatures in Immune-mediated Inflammatory Diseases: Initial Findings from the INTEGRATE Cohort Study
C000243	<b>014-6</b>	Oral Presentation 14	Friday, July 11, 2025	10:30 - 11:45	Room 6	IL411 regulates macrophage senescence and gut microbiota homeostasis in IBD
C000270	<b>014-7</b>	Oral Presentation 14	Friday, July 11, 2025	10:30 - 11:45	Room 6	Kushenol A modulates gut microbiota and repairs mucin sulfation modification disorder to alleviate ulcerative colitis
C000292	<b>014-8</b>	Oral Presentation 14	Friday, July 11, 2025	10:30 - 11:45	Room 6	Microbiota-induced S100B-RAGE axis mediates enteric glia-macrophage crosstalk and promotes colitis
C000294	<b>014-9</b>	Oral Presentation 14	Friday, July 11, 2025	10:30 - 11:45	Room 6	Christensenella minuta is trained by cholic acid to ameliorates colitis by modulating gut metabolism
C000408	<b>014-10</b>	Oral Presentation 14	Friday, July 11, 2025	10:30 - 11:45	Room 6	Early-Life Microbial Deprivation Impairs the Ontogeny of Intestinal tissue resident memory T cells and Exacerbates Ulcerative Colitis Pathogenesis
C000358	<b>014-11</b>	Oral Presentation 14	Friday, July 11, 2025	10:30 - 11:45	Room 6	Salivary Exosomal SAA1/2 Drive Gut Inflammation via the Oral-Gut Axis in Active IBD
C000026	<b>014-12</b>	Oral Presentation 14	Friday, July 11, 2025	10:30 - 11:45	Room 6	Protective effects of Lactacaseibacillus rhamnosus GG on gut inflammation in zebrafish
C000008	<b>015-1</b>	Oral Presentation 15	Friday, July 11, 2025	14:00 - 15:15	Room 6	Circadian clock component PER2 negatively regulates CD4 <sup>+</sup> T cell IFN- $\gamma$ production in ulcerative colitis



AOCC2025 - List of Accepted Abstracts (Oral Presentation)

Submission No. 	Presentation No.	Session	Date	Time	Room	The title of abstract
C000010	<b>O15-2</b>	Oral Presentation 15	Friday, July 11, 2025	14:00 - 15:15	Room 6	Amphiregulin-Driven Inflammatory Monocytes Promote Intestinal Fibrosis in Crohn's Disease through the EGFR-PI3K Signaling Pathway
C000060	<b>O15-3</b>	Oral Presentation 15	Friday, July 11, 2025	14:00 - 15:15	Room 6	RNF138 dysregulation exacerbates PUFA-induced ferroptosis of intestinal epithelial cells and aggravates colitis
C000062	<b>O15-4</b>	Oral Presentation 15	Friday, July 11, 2025	14:00 - 15:15	Room 6	Correlation of Lipocalin 2 Expression in Apical Enterocytes with Inflammation Severity in Inflammatory Bowel Disease
C000068	<b>O15-5</b>	Oral Presentation 15	Friday, July 11, 2025	14:00 - 15:15	Room 6	The protective role of Paneth cell metaplasia in the colonic epithelium of ulcerative colitis
C000070	<b>O15-6</b>	Oral Presentation 15	Friday, July 11, 2025	14:00 - 15:15	Room 6	The roles of Group2 innate lymphoid cells in intestinal inflammation
C000141	<b>O15-7</b>	Oral Presentation 15	Friday, July 11, 2025	14:00 - 15:15	Room 6	Deficient ATF7 Modulates Mitochondrial Dysfunction and Amplifies Intestinal Inflammation in Ulcerative Colitis
C000144	<b>O15-8</b>	Oral Presentation 15	Friday, July 11, 2025	14:00 - 15:15	Room 6	Downregulation of Circadian Gene Expression - Association with Inflammation and Sleep Disturbance in Inflammatory Bowel Disease
C000251	<b>O15-9</b>	Oral Presentation 15	Friday, July 11, 2025	14:00 - 15:15	Room 6	Unveiling the cellular and molecular insights into ulcerative colitis and its complications: a multi-omics investigation with functional experiments
C000253	<b>O15-10</b>	Oral Presentation 15	Friday, July 11, 2025	14:00 - 15:15	Room 6	Dihydroartemisinin Modulates Enteric Glial Cell Heterogeneity to Alleviate Colitis
C000285	<b>O15-11</b>	Oral Presentation 15	Friday, July 11, 2025	14:00 - 15:15	Room 6	Alleviates DSS Induced Colitis and fibrosis in Mouse by Targeting S1pr5 and Il36 $\gamma$
C000335	<b>O15-12</b>	Oral Presentation 15	Friday, July 11, 2025	14:00 - 15:15	Room 6	Escin attenuates DSS-induced colitis by Remodeling Macrophage Polarization Through NF-kappa B Signaling.
C000433	<b>O15-13</b>	Oral Presentation 15	Friday, July 11, 2025	14:00 - 15:15	Room 6	High-fat/high-sucrose Diet Exacerbates Colitis via HIF-2 $\alpha$ /LDHA-Mediated Histone H3K27 Lactylation
C000405	<b>O16-1</b>	Oral Presentation 16	Friday, July 11, 2025	15:30 - 16:45	Room 6	Bone Morphogenetic Protein 9 Stabilizes Gut Vascular Barrier in Refractory Ulcerative Colitis
C000441	<b>O16-2</b>	Oral Presentation 16	Friday, July 11, 2025	15:30 - 16:45	Room 6	Single cell transcriptomic analysis reveals insights into immunosenescence in the progression of ulcerative colitis
C000443	<b>O16-3</b>	Oral Presentation 16	Friday, July 11, 2025	15:30 - 16:45	Room 6	Succinate drives gut inflammation by promoting FoxP3 degradation through a molecular switch
C000396	<b>O16-4</b>	Oral Presentation 16	Friday, July 11, 2025	15:30 - 16:45	Room 6	Causal Effects of Ulcerative Colitis on Immune-Mediated Inflammatory Diseases in Japanese Population: A Mendelian Randomization Study
C000100	<b>O16-5</b>	Oral Presentation 16	Friday, July 11, 2025	15:30 - 16:45	Room 6	Impact of Hypercoagulable State on Crohn’s Disease Severity and Progression: Transcriptomic and Single-Cell Analyses of the Ileum
C000063	<b>O16-6</b>	Oral Presentation 16	Friday, July 11, 2025	15:30 - 16:45	Room 6	Lactobacillus rhamnosus GG derived p40 protein restrains immune checkpoint inhibitor-related colitis by limiting cGAS/STING pathway activation
C000194	<b>O16-7</b>	Oral Presentation 16	Friday, July 11, 2025	15:30 - 16:45	Room 6	TIMP1-Driven Macrophage Lactylation via cGAS-STING Activation Enhances Glycolysis and Senescence-Mediated Inflammation in Ulcerative Colitis
C000210	<b>O16-8</b>	Oral Presentation 16	Friday, July 11, 2025	15:30 - 16:45	Room 6	HDAC3 Exacerbates Intestinal Barrier Injury in Ulcerative Colitis by Inducing mtDNA Leakage and Activating the cGAS/STING Pathway
C000389	<b>O16-9</b>	Oral Presentation 16	Friday, July 11, 2025	15:30 - 16:45	Room 6	METTL3 potentiates aged CD4 <sup>+</sup> T cell response and accelerates elderly ulcerative colitis via programming effector differentiation
C000407	<b>O16-10</b>	Oral Presentation 16	Friday, July 11, 2025	15:30 - 16:45	Room 6	Inhibiting METTL3 in macrophages alleviates colitis by enhancing M2 polarization via upregulating IRAK-M
C000365	<b>O16-11</b>	Oral Presentation 16	Friday, July 11, 2025	15:30 - 16:45	Room 6	The role of mesenteric inflammation-associated fibroblasts in the development of Crohn’s disease
C000336	<b>O16-12</b>	Oral Presentation 16	Friday, July 11, 2025	15:30 - 16:45	Room 6	SINGLE-NUCLEUS SEQUENCING REVEALS THE HETEROGENEITY OF ADIPOCYTES IN CREEPING FAT OF CROHN’S DISEASE
C000334	<b>O16-13</b>	Oral Presentation 16	Friday, July 11, 2025	15:30 - 16:45	Room 6	Optimizing the Creeping Fat Animal Model of Crohn's Disease Through Repeated Biopsy Combined with DSS Stimulation